Lipton A, Santen R J, Harvey H A, Manni A, Simmonds M A, White-Hershey D, Bartholomew M J, Walker B K, Dixon R H, Valdevia D E
Am J Clin Oncol. 1987 Feb;10(1):65-70. doi: 10.1097/00000421-198702000-00015.
Recent reports have suggested that the sensitivity to chemotherapy of endocrine-dependent breast cancer may be enhanced by transient exposure to hormonal stimulation. To test this concept, 39 postmenopausal women with proven metastatic breast carcinoma and measurable disease were entered into this prospective, double-blind trial; 35 are currently evaluable. All patients were continuously treated with aminoglutethimide and hydrocortisone to lower estrogen production, plus cyclic chemotherapy. Patients in the "stimulation" arm received in addition, Estrace 2 mg b.i.d. sublingually for 3 days before and on the day of chemotherapy. Estrace administration appeared to accelerate tumor growth as demonstrated by increased bone pain, hypercalcemia, and growth of skin lesions. Response rates, response duration, and survival were similar in the stimulation and control groups.
最近的报告表明，短暂暴露于激素刺激下可能会增强内分泌依赖性乳腺癌对化疗的敏感性。为了验证这一概念，39名经证实患有转移性乳腺癌且疾病可测量的绝经后妇女进入了这项前瞻性双盲试验；目前有35名患者可进行评估。所有患者均持续接受氨鲁米特和氢化可的松治疗以降低雌激素生成，并联合进行周期性化疗。“刺激”组的患者在化疗前3天及化疗当天还额外接受每天两次、每次2毫克的雌二醇舌下含服，共3天。雌二醇给药似乎加速了肿瘤生长，表现为骨痛加剧、高钙血症和皮肤病变增大。刺激组和对照组的缓解率、缓解持续时间和生存率相似。
